Logo

Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

Share this

Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

Shots:

  • Abbott to get non-exclusive license rights for Banyan’s TBI biomarkers- including Ubiquitin Carboxy-terminal Hydrolase-L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP) kit to utilize it on its laboratory instruments
  • The focus of the agreement is to develop TBI assessment blood test for the patient with traumatic brain injury in the US and worldwide
  • Banyan BTI is the first blood test used for identification of biomarkers GFAP and UCH-L1 released from the brain and consists of two test kits Banyan GFAP and Banyan UCH-L1 providing ease to physicians to detect TBIs 

Ref: Business Wire | Image:  Abbott

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions